Hepatitis B

Preventing HBV Reactivation During Immunosuppressive Treatment

Preventing HBV Reactivation During Immunosuppressive Treatment

By

Although it is commonly accepted that lamivudine prophylaxis should be started a few weeks before chemotherapy is administered, the best time for lamivudine discontinuation is still controversial.

FDA Approves New Hepatitis B Vaccine for Adults

FDA Approves New Hepatitis B Vaccine for Adults

By

The FDA approves new hepatitis B virus vaccine for adults.

Aspirin May Lower Risk of HBV-Related Hepatocellular Carcinoma

Aspirin May Lower Risk of HBV-Related Hepatocellular Carcinoma

By

Patients who take aspirin may significantly reduce their risk of hepatitis B-related hepatocellular carcinoma.

Treating Hepatocellular Carcinoma: A Fight Against the Odds

Treating Hepatocellular Carcinoma: A Fight Against the Odds

By

Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are diagnosed at an advanced stage of the disease.

Hepatitis B Reactivation Rate Linked to Inflammatory Arthritis Treatment

Hepatitis B Reactivation Rate Linked to Inflammatory Arthritis Treatment

By

Hepatitis B virus reactivation rates differ in patients with inflammatory arthritis.

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

By

HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.

AAP: Hepatitis B Vaccine Should Be Given Within 24 Hours of Birth

AAP: Hepatitis B Vaccine Should Be Given Within 24 Hours of Birth

The first dose of the hepatitis B vaccine should be given within the first 24 hours of life.

Hepatitis B: Search for the Cure and Challenges That Remain

Hepatitis B: Search for the Cure and Challenges That Remain

By

One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access to suitable treatment.

New WHO Guidelines for Hepatitis B Virus Vaccine

New WHO Guidelines for Hepatitis B Virus Vaccine

By

The World Health Organization published a position paper with updated recommendations on the use of the hepatitis B vaccine regarding target groups, immunization schedules, and storage and distribution.

Subcirrhotic Liver Stiffness Cuts HCC Risk in Hepatitis B

Subcirrhotic Liver Stiffness Cuts HCC Risk in Hepatitis B

For patients with chronic hepatitis B, achievement of subcirrhotic range of liver stiffness with antiviral therapy is linked to lower risk of hepatocellular carcinoma.

Telbivudine During Early Pregnancy Prevents HBV Transmission

Telbivudine During Early Pregnancy Prevents HBV Transmission

By

A study showed that telbivudine administered during early and middle pregnancy prevented transmission of hepatitis B virus infection from mother to infants in all participants receiving antiviral treatment.

Entecavir/Tenofovir Tx for Chronic HBV Beyond 5 Years Decreases HCC Rate

Entecavir/Tenofovir Tx for Chronic HBV Beyond 5 Years Decreases HCC Rate

Hepatocellular carcinoma decreases beyond year 5 of entecavir/tenofovir therapy in Caucasian patients with chronic hepatitis B virus.

Screening for Viral Hepatitis Recommended Before Biologics in RA

Screening for Viral Hepatitis Recommended Before Biologics in RA

By

The Turkish Society of Rheumatology proposed a guideline of hepatitis screening in patients with rheumatoid arthritis.

HBV Vaccine Prevents Non-Hodgkin Lymphoma in Adolescents

HBV Vaccine Prevents Non-Hodgkin Lymphoma in Adolescents

By

Universal vaccination against hepatitis B virus infection prevented non-Hodgkin lymphoma in adolescents in Taiwan, an endemic area for hepatitis B virus infection.

HBV Reactivation: A Safety Concern With DAA Use in HBV/HCV Coinfection

HBV Reactivation: A Safety Concern With DAA Use in HBV/HCV Coinfection

Hepatitis B virus reactivation has become a safety concern in patients with HBV and HCV coinfection receiving direct-acting antiviral agents.

Tenofovir During Pregnancy Prevents Prenatal Transmission of HBV

Tenofovir During Pregnancy Prevents Prenatal Transmission of HBV

By

Women with a high hepatitis B viral load who receive tenofovir during pregnancy have a significantly reduced risk for passing on the virus to their child, without an increase in the risk of adverse events.

New EASL Guidelines for Managing Hepatitis B Virus Infection

New EASL Guidelines for Managing Hepatitis B Virus Infection

By

The new European Association for the Study of the Liver (EASL) clinical practice guidelines for hepatitis B virus infection identifies new management strategies for an incurable disease.

Statins Reduce Risk of Cirrhosis Decompensation in HBV, HCV

Statins Reduce Risk of Cirrhosis Decompensation in HBV, HCV

By

Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and, to a lesser extent, in patients with alcohol-induced cirrhosis. Mortality rates were also reduced in statin users with HBV-related cirrhosis.

Hepatitis B and C Infection May Increase Risk for Parkinson Disease

Hepatitis B and C Infection May Increase Risk for Parkinson Disease

By

While prior studies have found an association between hepatitis C and the risk for Parkinson disease, the association between hepatitis B and Parkinson disease is new and needs further confirmation.

HBV, HCV Could Be Wiped Out as Public Health Threats by 2030

HBV, HCV Could Be Wiped Out as Public Health Threats by 2030

Despite being the seventh leading cause of death in the world, viral hepatitis accounts for less than 1% of the National Institutes of Health research budget.

Rate of HBV Reactivation in Chronic Hepatitis C Patients Receiving DAAs

Rate of HBV Reactivation in Chronic Hepatitis C Patients Receiving DAAs

Hepatitis B virus reactivation may occur in patients with chronic hepatitis C with current HBV infection treated with direct-acting antivirals.

Abnormal Bone Metabolism With Tenofovir for HBV Infection

Abnormal Bone Metabolism With Tenofovir for HBV Infection

By

Long-term treatment with tenofovir for hepatitis B virus infection is associated with hypophosphatemia and elevated serum levels of fibroblast growth factor 23, a hormone that induces renal phosphate excretion.

Clinical Guideline on Evaluating Abnormal Liver Chemistries

Clinical Guideline on Evaluating Abnormal Liver Chemistries

By

The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

By

Meta-analysis provides further support to findings that show a protective role of antibody to hepatitis B surface antigen against reactivation in patients with resolved HBV undergoing chemotherapy for hematologic tumors without antiviral prophylaxis.

Short-Course Tocilizumab May Increase HBV Reactivation in RA

Short-Course Tocilizumab May Increase HBV Reactivation in RA

Three-dose tocilizumab combined with csDMARDs might increase the risk of HBV reactivation in RA patients with chronic HBV infection.

Prophylactic Lamivudine Reduces HBV Flares During Chemotherapy

Prophylactic Lamivudine Reduces HBV Flares During Chemotherapy

By

Patients with breast cancer who have chronic HBV infection have fewer flares while undergoing chemotherapy if they are treated with prophylactic lamivudine.

Multiple Updates for Atazanavir and Cobicistat HIV Combination Tx

Multiple Updates for Atazanavir and Cobicistat HIV Combination Tx

By

Evotaz label has been updated to include data from Trial 114 including updates to the drug interactions and specific populations sections.

First HBV Quantitative Test to Assess Antiviral Therapy Response

First HBV Quantitative Test to Assess Antiviral Therapy Response

By

The new HBV test service from Quest Diagnostics measures the quantity of viral antigen to determine if the immune system is responding to treatment.

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Meta-analysis shows consistent evidence that in advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival is dependent on patients' hepatitis status.

ART Improves Liver Fibrosis in Majority of Patients With HIV

ART Improves Liver Fibrosis in Majority of Patients With HIV

By

Combination antiretroviral therapy is associated with an overall reduction in liver fibrosis in HIV-infected patients with and without hepatitis co-infections.

Sign Up for Free e-newsletters